immunomodulators and biologics maria t. abreu, md university of miami miller school of medicine...
TRANSCRIPT
Immunomodulators and Biologics
Maria T. Abreu, MD
University of Miami Miller School of Medicine
Miami, Florida
Management of Post-Operative Recurrence of IBD
David T. Rubin, MD, AGAFAssociate Professor of Medicine
Co-Director, Inflammatory Bowel Disease CenterUniversity of Chicago Medicine
IBD
Induction of remission
Maintenance of remission off steroids
and/orMucosal healing
(histology)
Maintenance of remission
What do we know: Guiding principles
Combination therapy is better than monotherapy
Early therapy is better than late therapy (esp Crohn’s disease)
Well timed surgery is ok
Indications for Surgery
Crohn’s disease: Obstruction Medically refractory disease Hemorrhage/transfusion requirements High grade dysplasia or cancer Growth delay Fistula/abscess
Ulcerative colitis: Medically refractory disease/fulminant disease High grade dysplasia or cancer Hemorrhage/transfusion requirements Perforation
Chimeric monoclonal antibody (75% humanIgG1 isotype)
Infliximab
IgG1
Mouse HumanPEG, polyethylene glycol.
Humanized Fab’fragment (95% humanIgG1 isotype)
Certolizumab Pegol
PEG
PEG
VHVL
CH1
No Fc
Human recombinant antibody (100% humanIgG1 isotype)
Adalimumab
IgG1
First-line Biologic Agents for the Treatment of CD
SONIC
• Moderate-to-severe CD in patients with no prior exposure to biologic agents or immunomodulators• Excluded intermediate TPMT activity• Average disease duration 2.3 years
• 1° endpoint: Induction + maintenance of steroid-free remission
• 2° endpoint: Mucosal healing
AZA 2.5mg/kg IFX 5mg/kg IFX + AZA
Clinical Remission Without Corticosteroids at Week 26
SONIC 9
Primary Endpoint
30
45
57
0
20
40
60
80
100
Pro
po
rtio
n o
f P
atie
nts
(%
)
AZA + placebo IFX + placebo IFX+ AZA
p<0.001
p=0.009 p=0.022
52/170 75/169 96/169
Colombel, J.F., et al., N Engl J Med. 362(15): p. 1383-95.
Cumulative Probability of Surgeryin Crohn’s Disease
Mekhjian HS et al. Gastroenterol. 1979;77(4 pt 2):907-913.
Pati
en
ts*
(%)
0
20
40
60
80
100
0 5 10 15 20 25 30 35Years After Onset
Preoperative Corticosteroids Increase Risk of Postoperative Complications in IBD
Minor Complications
Major Complications*
CS 3.69 (1.24–10.97) 5.54 (1.12–27.26)
CS <20 mg 2.56 (0.68–9.61) 6.28 (0.97–40.36)
CS 30–40 mg 3.12 (0.93–10.49) 5.87 (0.90–38.23)
CS >40 9.16 (1.51–55.42) 18.94 (1.72–207.34)
6-MP/AZA 1.68 (0.65–4.27) 1.2 (0.37–3.94)
6-MP <1.5 mg/kg 1.49 (0.56–3.98) 1.12 (0.32–3.93)
6-MP>1.5 mg/kg 4.50 (0.46–44.51) 1.89 (0.32–3.93)
• 159 IBD patients (71 UC, 88 CD) undergoing elective bowel surgery
Aberra FN et al. Gastroenterology. 2003;125:320.
*Major complications include sepsis, pneumonia, peritonitis, abscess, wound infection
CS, corticosteroids; 6-MP, 6-mercaptopurine; AZA, azathioprine
TNF Use Prior to Surgery
• Postoperative infections– CD1: Mayo Clinic
• 52 IFX vs 218 no IFX • OR 0.9 (95% CI 0.4–1.9)1
– UC2: Mayo Clinic • 47 IFX vs. 254 no IFX • OR 2.7 (95% CI 1.1–6.7)
– UC3: Cleveland Clinic • Pelvic sepsis • 46 IFX vs. 46 no IFX • OR 13.8 (1.8–105)
1. Colombel JF et al. Am J Gastroenterol. 2004;99:878. 2. Selvasekar CR et al. J Am Coll Surg. 2007;204:956.
3. Mor IJ. Dis Col Rectum. 2008;51:1202.
CD
UC
?
IFX, infliximab; OR, odds ratio; CI, confidence interval
Disability
Post-op Ileocecectomy is the Perfect Opportunity for Prevention!
DiseasePrevention
Prevention ofSymptomatic Disease
Prevention ofComplications
Prevention ofRelapse
Health SubclinicalInflammation
SymptomaticInflammation
Complications
Recurrence After Surgery in Crohn’s Disease
Rutgeerts P et al. Gastroenterol. 1990;99(4):956-963.
Years
Pat
ient
s (%
)
Survival without surgery
0
20
40
60
80
100
0 1 2 3 4 5 6 7 8
Survival without symptoms
Survival withoutlaboratory recurrence
Survival withoutendoscopic lesions
N=89
Risk Stratification for Recurrence in Post-operative Crohn’s disease
SmokingPerforating-type of
diseaseSmall bowel diseaseIleocolonic disease
Perianal fistulasDuration of diseaseAge? Clear margins? Length of resection?Type of anastomosis
Greenstein AJ et al. Gut. 1988;29(5):588-592. Bernell O et al. Ann Surg. 2000;231(1):38-45. Bernell O et al. Br J Surg. 2000;87(12):1697-1701. D'Haens GR et al. Gut. 1995;36(5):715-717. Lautenbach E et al. Gastroenterol.1998;115(2):259-267. Moskovitz D et al. Int J Colorectal Dis. 1999;14(4-5):224-226. Kono T et al. Dis Colon Rectum 2011 May;54(5):586-92.
The Neo-TI: The Rutgeerts’ ScorePatients should be scoped 6 months after surgery
to re-stratify risk
Normal ileal mucosa
Rutgeerts 0
<5 aphthous ulcers
Rutgeerts 1
>5 aphthous ulcers, normal intervening mucosa
Rutgeerts 2
Ulceration without normal intervening mucosa
Severe ulceration with nodules, cobblestoning, or stricture
Rutgeerts 3 Rutgeerts 4
The neo-terminal ileum is not the anastomosis!
• Suture-related trauma• Marginal ulcerations/ischemia
Symptoms after Crohn’s Surgery are Not Always Inflammatory!
Symptom/Cause TreatmentsPost-operative pain Limited analgesia, regional
anesthesia when possible
Post-resection “diarrhesis” (rapid transit due to absence of obstruction and muscular hypertrophy)
Anti-diarrheals
Bile salts Bile acid sequestrant
Narcotic bowel NO narcotics!
Bacterial overgrowth antibiotics
Clinical Recurrence Endoscopic recurrence
Placebo 25% – 77% 53% - 79%
5 ASA 24% - 58% 63% - 66%
Budesonide 19% - 32% 52% - 57%
Nitroimidazole 7% - 8% 52% - 54%
AZA/6MP 34% – 50% 42 – 44%
Infliximab 0% 9.1%
Regueiro M. Inflamm Bowel Dis. 2009 Oct;15(10):1583-90.
Medical Prevention of Clinical and Endoscopic Recurrence of Crohn’s Disease
Endoscopic Clinical
Thiopurines for the prevention of postoperative recurrence in Crohn’s disease: meta-analysis
Peyrin-Biroulet L et al. Am J Gastroenterol. 2009 Aug;104(8):2089-96.
Metronidazole/azathioprine combination therapy for post-operative recurrence
– High risk pts (n=81) = (age <30, smokers, steroids <3 months, second resection, perforated/abscess)
– N=40 metronidazole 250 mg TID 3 months + AZA 2–3 tabs– N=41 metronidazole 250 mg TID 3 months + placebo
D'Haens GR et al. Gastroenterology. 2008 Oct;135(4):1123-9.
53
69
3.4
34
44
22
0
20
40
60
80
Month 3 Month 12 No lesions at Month 12
Placebo
Combination therapyp=0.11
p=0.048
p=0.03
% p
atie
nts
with
end
osco
pic
recu
rren
ce (
>i2
) po
st s
urge
ry
0
10
20
30
40
50
60
70
80
90
Endoscopic Recurrence
% p
atie
nts
Infliximab (n=11) Placebo (n=13)
Infliximab vs placebop=0.0006
Endoscopic Recurrence defined as endoscopic scores of i2, i3, or i4. Regueiro M et al. 2009 Feb;136(2):441-50.e1; quiz 716.
1/11 11/13
Post-operative Endoscopic RecurrenceInfliximab vs. Placebo
Assess risk of recurrence
Low Moderate HighDon’t Know
Therapy? Start therapy Start therapy ?
Thiopurine + MTX
TNF + IMM
Colonoscopy at 6 months
Colonoscopy at 6 months
Colonoscopy at 6 months
Colonoscopy at 3-6 months
Metronidazole at dischargeMetronidazole at discharge
i0-i1 i2-i4 i0-i1 i2-i4 i0-i1 i2-i4
Follow up
TreatmentEscalate
Rx Change dose/ optimization
4 weeks4 weeks
Metronidazole at discharge
Proposed Algorithm for Prevention of Post-Op Recurrence in Crohn’s
Ulcerative colitis
Early mucosal healing a favorable prognostic factor in UC
Infliximab-treated patientsP<0.0001
Patie
nts
in C
ortic
oste
roid
-fre
e re
mis
sion
%
Week 8 endoscopic score
ACT 1 and ACT 2
Colombel JF et al. Gastroenterology. 2011 Jun 29. [Epub ahead of print].
Week 8 endoscopy
Can Surgery for UC be Prevented?Mucosal Healing and Time to Colectomy in Infliximab-Treated Patients
1 = MILD 2 = MODERATE 3 = SEVERE0 = NORMAL
Colombel JF, Rutgeerts P, Reinisch W, et al. Gastroenterology. 2011 Oct;141(4):1194-201
Ulcerative Colitis: Ileo-pouch Anal Anastomosis
Colectomy
J pouch
Cuff/Anal Transition zone
Better Outcomes at High Volume Hospitals
OR = 1.18 (0.99–1.41)
Kaplan GG et al. Gastroenterology. 2008;134:680.
Per
cen
t
50
40
30
20
10
0
35.4
25.6
OR = 2.42 (1.26–4.63)
4.0 0.7
Mortality Complications
Low volume High volume
“Complications” of the Ileal Pouch
Compliments of Bo Shen, MD
Surgical/MechanicalSurgical/
MechanicalInflammatory/
InfectiousInflammatory/
Infectious FunctionalFunctional Dysplasia/NeoplasiaDysplasia/Neoplasia
Systemic/MetabolicSystemic/Metabolic
- Afferent limb syn.- Efferent limb syn.- Strictures- Leaks- Fistulae- Sinuses- Abscess- Adhesions- Re-operation
- Afferent limb syn.- Efferent limb syn.- Strictures- Leaks- Fistulae- Sinuses- Abscess- Adhesions- Re-operation
- Pouchitis- Crohn’s dis.- Cuffitis- Small bowel bacterial overgrowth- CMV - C. difficile - Polyps
- Pouchitis- Crohn’s dis.- Cuffitis- Small bowel bacterial overgrowth- CMV - C. difficile - Polyps
- Irritable pouch syn.- Pelvic floor dysfunction- Poor pouch compliance- Pseudo- obstruction
- Irritable pouch syn.- Pelvic floor dysfunction- Poor pouch compliance- Pseudo- obstruction
- Anemia- Osteoporosis- Vitamin B12 deficiency- Malnutrition- Fertility- Sexuality
- Anemia- Osteoporosis- Vitamin B12 deficiency- Malnutrition- Fertility- Sexuality
- Dysplasia- Cancer
- Dysplasia- Cancer
Risk Factors for Pouchitis
• Extensive UC• Backwash ileitis• Primary sclerosing cholangitis• p-ANCA• NOD2/ IL-1 receptor antagonist
polymorphisms• Ex-smoker• NSAIDs• Arthralgias• Family history of Crohn’s disease
Fazio VW et al. Ann Surg. 1995 August; 222(2): 120–127; Schmidt CM et al. Ann Surg. 1998 May; 227(5): 654–665; J L Lohmuller et al. Ann Surg. 1990 May; 211(5): 622–629; Fleshner P et al. Clin Gastroenterol Hepatol. 2007 Aug;5(8):952-8; quiz 887; Achkar JP et al.Clin Gastroenterol Hepatol. 2005 Jan;3(1):60-6; Shen B et al. Am J Gastroenterol. 2005 Jan;100(1):93-101; Le Q et al. Inflamm Bowel Dis. 2012 Mar 29 [Epub ahead of print]
Figure: http://www.webmd.com accessed May, 2012.
Infrequent Relapse
Infrequent Relapse
Frequent Relapse
Frequent Relapse
Antbx-dependentPouchitis
Antbx-dependentPouchitis
Antbx-responsive Pouchitis
Antbx-responsive Pouchitis
RespondedResponded Not RespondedNot Responded
Cipro or Metronidazole x 2 more wksCipro or Metronidazole x 2 more wks
RespondedResponded Not RespondedNot Responded
Cipro+ Metronidazole or Rifaximin or Tinidazole x 4 wks
Cipro+ Metronidazole or Rifaximin or Tinidazole x 4 wks
Antbx-refractoryPouchitis
Antbx-refractoryPouchitis
Not RespondedNot Responded
5-ASA/steroids/Immunomodulators/Infliximab?
5-ASA/steroids/Immunomodulators/Infliximab?
Antibiotics prnAntibiotics prn Probiotics or Antibiotics
Probiotics or Antibiotics
Cipro or Metronidazole x 2 wksCipro or Metronidazole x 2 wks
PouchitisPouchitis
Management of Pouchitis(endoscopic confirmation is preferred)
Can Pouchitis be Prevented?Frequency of Pouchitis with Probiotic
Prophylaxis
10%
40%
0
20
40
60
80
100
VSL3 Placebo
Gionchetti P et al. Gastroenterol 2003 May;124(5):1202-9.
N = 206 grams QD x 12 months
N = 20
P < 0.05%
case
s w
ith fl
are
-up
Key Take Home Messages
IBD
• Stratify patients for disease severity & potential long-term complications
• Combination therapy better than monotherapy for sick patients naïve to both
• Low Absolute risk of IS or Biologic therapy • Vaccines, DXAs and other health
maintenance issues will eventually be used to measure quality
Risks of IBD Therapy
• Non-melanoma skin cancer (NMSC) associated with current or past IS therapy
• No other solid tumors show clear association with IS or anti-TNF therapy
• No clear signal that combination therapy leads to higher risk than monotherapy
• HSTCL occurs AFTER 2 years of thiopurine exposure
• Risk of PML after 2 years on natalizumab about 1 in 100 exposed patients
Management of Post-operative Recurrence in IBD
• Know patient’s risk of recurrence• Confirm endoscopic disease• Ulcerative colitis
– Mucosal healing reduces risk of colectomy– Assess risk of pouchitis– Distinguish pouchitis/Crohn’s/pre-pouch ileitis
• Crohn’s disease (ileo-colonic anastomosis)– Assess colonoscopic recurrence @ 6 months– Prophylaxis vs re-treatment based on risks and treatment
history – Subsequent clinical/endoscopic f/u not defined
Microscopic colitis
• Incidence appears to have stabilized• Consider celiac disease if steatorrhea or
weight loss• Consider drug-induced MC • Treat with bismuth or budesonide
– -Right dose and right duration• Maintenance therapy with budesonide is
effective
Gut microbiota and IBS
• Microbiota in IBS:– Differs from health & may contribute to
pathogenesis– May lead novel diagnostic tests for IBS– May select or predict response to IBS
treatments treatments– Provide potential target in IBS
• Antibiotics, Probiotics, Therapeutic foods